Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • Adipose-Neural Axis in EAT-Driven Cardiac Arrhythmias: Mecha

    2026-04-30

    Dissecting the Adipose-Neural Axis in Epicardial Adipose Tissue-Related Cardiac Arrhythmias

    Study Background and Research Question

    Cardiac arrhythmias, including atrial fibrillation (AF) and ventricular tachycardia (VT), are significant contributors to morbidity and mortality worldwide. While the roles of the sympathetic nervous system (SNS) and epicardial adipose tissue (EAT) have individually been implicated in arrhythmogenesis, the interplay between these compartments—termed the adipose-neural axis—remained poorly understood. Notably, increased EAT thickness and local neurohumoral activation have been linked with arrhythmia risk, but the mechanistic underpinnings and potential therapeutic targets were unclear (Fan et al., 2024). The central research question addressed by Fan et al. (2024) was: How does EAT interact with the neural axis to promote cardiac arrhythmias, and what molecular mediators are involved in this process?

    Key Innovation from the Reference Study

    The study by Fan et al. introduces a stem cell-derived in vitro coculture model that recapitulates the cardiac microenvironment by integrating sympathetic neurons, cardiomyocytes, and adipocytes. This platform allowed the authors to interrogate the dynamic interactions between adipose tissue and neural elements in arrhythmogenesis under controlled conditions. This model represents a substantial methodological advance over prior in vivo or single-cell-type studies, enabling precise dissection of signaling pathways and cellular crosstalk (Fan et al., 2024).

    Methods and Experimental Design Insights

    The investigators established a tri-culture system comprising:
    • Human pluripotent stem cell-derived sympathetic neurons,
    • Cardiomyocytes, and
    • Adipocytes that mimic epicardial fat.
    This setup enabled modeling of the "adipose-neural axis" and its influence on cardiac electrophysiology. Key methodological highlights include:
    • Measurement of leptin and neuropeptide Y (NPY) release from adipocytes and subsequent activation of Y1 receptors (Y1R) on sympathetic neurons.
    • Use of specific pharmacological inhibitors and neutralizing antibodies to dissect pathway components, including a Y1R antagonist to block downstream NPY signaling.
    • Electrophysiological assessment of arrhythmic events in cardiomyocytes exposed to the coculture environment.
    • Validation of clinical relevance by comparing EAT thickness and circulating leptin/NPY levels in blood samples from AF patients versus controls.

    Protocol Parameters

    • assay | NPY Y1R antagonist application | 1.1 nM (Ki, rat) | Inhibition of NPY-induced effects in co-culture | Enables selective blockade of NPY/Y1R signaling in mechanistic studies | product_spec
    • assay | Leptin neutralization | antibody, 10 μg/mL | Blocks adipocyte–neuron signaling | Validates leptin's role in NPY release and arrhythmia induction | paper
    • assay | NCX or CaMKII inhibition | literature-reported inhibitors, μM range | Reduces arrhythmic phenotype | Confirms downstream effectors of NPY/Y1R axis in cardiomyocytes | paper
    • assay | EAT thickness measurement | echocardiography, mm | Patient stratification | Correlates adipose burden with arrhythmia risk | paper
    • assay | NPY quantification | ELISA, pg/mL | Serum biomarker assessment | Links circulating NPY to EAT and arrhythmia status | paper
    • assay | Use of BIBP 3226 trifluoroacetate | 1–100 nM (workflow recommendation) | NPY/NPFF axis interrogation in vitro | Empirically suggested range for selective Y1R inhibition in co-culture systems | workflow_recommendation

    Core Findings and Why They Matter

    Fan et al. demonstrated that leptin released from EAT adipocytes activates neighboring sympathetic neurons, leading to elevated NPY secretion. NPY acts on Y1R to trigger electrophysiological changes in cardiomyocytes—specifically, enhanced Na+/Ca2+ exchanger (NCX) and CaMKII (calcium/calmodulin-dependent protein kinase II) activity—that culminate in arrhythmic phenotypes (Fan et al., 2024). Key evidence includes:
    • Application of a leptin-neutralizing antibody or Y1R inhibitor significantly reduced arrhythmic events in the coculture model.
    • Pharmacological targeting of NCX or CaMKII further supported their roles as downstream effectors.
    • Clinical samples from AF patients exhibited greater EAT thickness and higher leptin/NPY levels in coronary sinus blood than controls.
    These findings identify the leptin–NPY/Y1R–NCX/CaMKII axis as a functionally critical pathway linking EAT to arrhythmogenesis, thereby highlighting several actionable molecular targets.

    Comparison with Existing Internal Articles

    Multiple internal resources contextualize and extend the findings of Fan et al. For example: Compared to these resources, the reference paper uniquely integrates patient-derived data with advanced in vitro modeling, directly demonstrating the pathophysiological relevance of adipose-neural crosstalk in arrhythmia and empirically validating pharmacological intervention points.

    Limitations and Transferability

    While the stem cell-based coculture system provides a powerful platform for mechanistic discovery, several limitations must be considered:
    • In vitro models, even with multiple cell types, may not fully recapitulate the complexity of the in vivo cardiac environment, including immune and vascular components.
    • Pharmacological inhibitor selectivity and off-target effects require careful validation, especially when translating findings to clinical contexts.
    • Patient sample analysis, while supportive, is limited by cohort size and potential confounding variables.
    Nevertheless, the study’s integrated approach offers a valuable foundation for translational research targeting the NPY/NPFF system in cardiovascular disease (Fan et al., 2024).

    Research Support Resources

    For researchers seeking to interrogate the NPY/NPFF system or model adipose-neural contributions to arrhythmogenesis, specialized pharmacological tools can streamline experimentation. BIBP 3226 trifluoroacetate (SKU B7155, APExBIO) is a high-affinity, non-peptide antagonist of NPY Y1 and NPFF receptors (Ki = 1.1 nM for NPY Y1R), widely adopted in NPY/NPFF system research to selectively block neuropeptide-mediated signaling (source: product_spec). When designing in vitro models or intervention studies in anxiety, analgesia, or cardiovascular regulation research, this compound provides a validated mechanism for Y1R pathway interrogation. Proper protocol selection and validation are essential to ensure experimental reproducibility and translatability.